THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.2]-CMP149 ID: TIP-MED-000419

Dutasteride IP [12.2-CMP149] — Indian Pharmacopoeia Compendial Softgel & BPH Combination Profile

Active Ingredient / Scientific Identity: Dutasteride IP • Class: 5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversion of Testosterone to Potent Dihydrotestosterone [DHT] to Shrink Prostate Volume)

⚖️ Compare Profile
Generic / Entity NameDutasteride IP ([12.2]-CMP149)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological Class5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversion of Testosterone to Pot
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised ext
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Dutasteride IP (TIP-MED-000419, Reference Code [12.2]-CMP149) is classified under Urological & Renal Stone Medicines (Ch 12) as a 5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversion of Testosterone to Potent Dihydrotestosterone [DHT] to Shrink Prostate Volume). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Dual Type 1 & Type 2 5-alpha-reductase inhibitor (dedicated monograph [12.9]).
Dual Type 1 & Type 2 5-alpha-reductase inhibitor (dedicated monograph [12.9]).
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Dual Type 1 & Type 2 5-alpha-reductase inhibitor (dedicated monograph [12.9]).

4. Therapeutic Indications & Evidence-Supported Uses

  • Treatment and long-term progression prevention of moderate-to-severe Benign Prostatic Hyperplasia (BPH) with an enlarged prostate (>30–40 mL/grams)—uniquely shrinks prostate gland volume by 20–30%, reduces risk of Acute Urinary Retention (AUR) by >50%, and reduces need for TURP prostate surgery! (1 mg strength: male pattern baldness)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Dual Type 1 & Type 2 5-alpha-reductase inhibitor (dedicated monograph [12.9]).

Administration & Meal Timing: Plain Finasteride/Dutasteride: With or without food. If in FDC with Tamsulosin (Urimax-D / Urimax-F / Veltam-Plus): MUST be taken 30 minutes AFTER dinner! Swallow whole. | Once daily (in the evening 30 minutes after dinner if combined with tamsulosin).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [12.2].
Metabolism & Biotransformation:
Renal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised extensively in the liver (Note: Dutasteride has an extraordinarily long elimination half-life of 3 to 5 WEEKS vs Finasteride's 6–8 hours!)—use caution in liver disease and avoid in severe hepatic impairment.
Elimination & Renal Adjustment:
Renal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised extensively in the liver (Note: Dutasteride has an extraordinarily long elimination half-life of 3 to 5 WEEKS vs Finasteride's 6–8 hours!)—use caution in liver disease and avoid in severe hepatic impairment.
Hepatic Impairment Considerations:
Renal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised extensively in the liver (Note: Dutasteride has an extraordinarily long elimination half-life of 3 to 5 WEEKS vs Finasteride's 6–8 hours!)—use caution in liver disease and avoid in severe hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • 1. STRICT PREGNANCY TERATOGENICITY HANDLING BAN (Category X): Finasteride and Dutasteride inhibit DHT-dependent external genitalia differentiation in a male foetus (causing hypospadias/ambiguous genitalia)! Women who are pregnant or may become pregnant MUST NEVER take or even touch crushed, broken, or leaking Finasteride tablets or Dutasteride capsules (absorbed through skin)! 2. CRITICAL PROSTATE CANCER (PSA) MASKING RULE: Finasteride and Dutasteride reduce Serum Prostate-Specific Antigen (PSA) levels by approximately 50% within 6 months—even in the presence of prostate cancer!

Key Clinical Precautions: Renal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised extensively in the liver (Note: Dutasteride has an extraordinarily long elimination half-life of 3 to 5 WEEKS vs Finasteride's 6–8 hours!)—use caution in liver disease and avoid in severe hepatic impairment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Decreased libido (3–6%), erectile dysfunction (5–8%), ejaculatory disorders / decreased semen volume, mild gynaecomastia (breast enlargement/tenderness in 1–2% of men).
  • Male Breast Cancer (rare—instruct patients to report any unilateral breast lump, pain, or nipple discharge immediately!), depression/suicidal ideation (post-finasteride mood warning), high-grade prostate cancer detection delay if PSA is not doubled during interpretation, angioedema.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Minimal pharmacokinetic interactions (metabolised by CYP3A4 without inducing/inhibiting enzymes; itraconazole/diltiazem modestly raise dutasteride levels)

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.2].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: 3 Vital Counselling Points for Finast / Duprost / Urimax-D: 1. The 'PSA Doubling Rule' for Lab Reports: Tell every elderly gentleman: 'Whenever you get a PSA blood test for your prostate after taking Finasteride or Dutasteride for 6+ months, remind your doctor that you take this medicine—because this tablet cuts the PSA number in half, the doctor must MULTIPLY your lab PSA value by 2 to get your true PSA!' Furthermore, any rise in PSA while taking Finasteride/Dutasteride requires urgent urology review! 2. 6-Month Patience Rule: Do not stop the tablet after 1 month thinking it didn't shrink the prostate—gland shrinkage takes 3 to 6 months. 3. Pregnant daughters-in-law or female caregivers must never handle broken tablets or leaking capsules.
    • Meal & Clock Timing Instruction: Plain Finasteride/Dutasteride: With or without food. If in FDC with Tamsulosin (Urimax-D / Urimax-F / Veltam-Plus): MUST be taken 30 minutes AFTER dinner! Swallow whole. (Once daily (in the evening 30 minutes after dinner if combined with tamsulosin).)
    • Missed Dose Protocol: Take as soon as remembered on the same day; skip if close to next day's dose. Never double.
    • Geriatric Dispensing Pearl: Highly beneficial in elderly men with large prostates (>40 g) to prevent emergency catheterisation for acute urinary retention; always remind them about the PSA-doubling rule and breast lump check.

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Finasteride Film-Coated Tablets: 5 mg (BPH), 1 mg (Androgenetic Alopecia); Dutasteride Softgel Capsules: 0.5 mg (BPH)

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.